Trial Profile

A Phase 1b/2 Study of Talquetamab Plus Concomitant Priming Radiotherapy in Multiple Myeloma With Extramedullary Disease

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Talquetamab (Primary)
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

11 Apr 2025 Planned initiation date changed from 1 Mar 2025 to 1 Jul 2025.
13 Jan 2025 Planned initiation date changed from 15 Dec 2024 to 1 Mar 2025.
30 Aug 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com